Type
Results for
"[search-keyword]"
Sponsor content
176 result(s) found, displaying 1 to 10
- AlhemoPrescription medicine decision summaryAlhemo (concizumab) is approved to prevent haemophilia.
- SOGROYA somapacitan 15 mg (10 mg/mL) solution for injection prefilled pen (396878)ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOGROYA somapacitan 15 mg (10 mg/mL) solution for injection prefilled pen.
- SOGROYA somapacitan 5 mg (3.3 mg/mL) solution for injection prefilled pen (396877)ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOGROYA somapacitan 5 mg (3.3 mg/mL) solution for injection prefilled pen.
- AlhemoPrescription medicine decision summaryTGA decision: Alhemo is approved where prophylaxis is required to prevent or reduce the frequency of bleeding in patients at least 12 years of age who have haemophilia B.
- ALHEMO concizumab 300 mg / 3 mL solution for injection prefilled pen (394066)ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALHEMO concizumab 300 mg / 3 mL solution for injection prefilled pen.
- ALHEMO concizumab 60 mg / 1.5 mL solution for injection prefilled pen (394065)ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALHEMO concizumab 60 mg / 1.5 mL solution for injection prefilled pen.
- ALHEMO concizumab 15 mg / 1.5 mL solution for injection prefilled pen (394068)ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALHEMO concizumab 15 mg / 1.5 mL solution for injection prefilled pen.
- ALHEMO concizumab 150mg / 1.5 mL solution for injection prefilled pen (394067)ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALHEMO concizumab 150mg / 1.5 mL solution for injection prefilled pen.
- ALHEMO (Novo Nordisk Pharmaceuticals Pty Ltd)Prescription medicine registrationActive ingredients: concizumab.
- EsperoctPrescription medicine decision summaryTGA decision: Esperoct (turoctocog alfa pegol) is approved to treat haemophilia A.